JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) (JEMS)
The objective of the study is to estimate the prevalence of anti-JCV antibodies in multiple sclerosis (MS) participants.
|Study Design:||Time Perspective: Cross-Sectional|
|Official Title:||Epidemiology of Anti-JCV Antibody Prevalence in Multiple Sclerosis Patients|
- Prevalence of anti-JCV antibodies [ Time Frame: Single timepoint (Day 1) ] [ Designated as safety issue: No ]Prevalence of anti-JCV antibodies will be estimated as the number of participants with anti-JCV antibodies detected in serum divided by the total number of participants with a serum sample that was evaluated.
|Study Start Date:||September 2010|
|Study Completion Date:||June 2012|
|Primary Completion Date:||May 2012 (Final data collection date for primary outcome measure)|
This is a cross-sectional, multi-center, multi-national, epidemiological study to estimate the prevalence of anti-JCV antibody in MS participants. This study will provide an estimate of the prevalence of anti-JCV antibody in the MS population and will investigate inter-country differences.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01185717
|Study Director:||Medical Director||Biogen Idec|